摘要
目的 比较中、低剂量重组人凝血因子Ⅷ防治血友病A关节出血的临床疗效.方法将58 例血友病A患儿按预防剂量的大小分为2组：中剂量组（28例）和低剂量组（30例）.中剂量组采用重组人凝血因子Ⅷ15～25 ·kg-1静脉推注,3次周-1,连用4个月;低剂量组采用重组人凝血因子Ⅷ＜15 U·kg-1静脉推注,3次＆#183;周-1,连用4个月.观察2组防治前、防治4个月后关节出血次数的情况.结果 2组防治4个月后关节出血次数明显低于防治前（P＜0.05）,中剂量组防治4个月后关节出血次数明显低于低剂量组（P＜0.05）.结论 重组人凝血因子Ⅷ用于防治血友病A能明显改善关节出血症状,且中剂量防治优于低剂量.
Objective To compare the clinical efficacy of medium and low dose recombinant co- agulation factor in the prevention and treatment of joint bleeding in children with hemophilia A. Methods A total of 58 children with hemophilia A were intravenously injected recombinant coagulation factor at medium dose（15-25 U · kg-1 ,28 children） or low dose（〈15 U · kg-1 ,30 children） 3 times per week for 4 months. The frequency of joint bleeding was observed before and 4 months after prevention and treatment. Results The frequency of joint bleeding significantly reduced in both groups 4 months after prevention and treatment（P〈0.05）. Compared with low dose group, the frequency of joint bleeding significantly decreased in medium dose group （P 〈0.05）. Conclusion Recombinant coagulation factor Ⅷcan improve joint bleeding in children with hemophilia A in a dose-dependent manner.
出处
《南昌大学学报（医学版）》
CAS
2013年第12期40-42,共3页
Journal of Nanchang University：Medical Sciences
基金
江西省卫生厅科技计划(20113006)
关键词
血友病
重组人凝血因子Ⅷ
疗效
防治
hemophilia recombinant coagulation factor Ⅷ curative efficacyprevention and treatment
